Inhibition of vascular smooth muscle cell growth by inhibition of fibronectin matrix assembly.
The regulation of vascular smooth muscle cell (VSMC) proliferation by the fibronectin matrix was tested by treating human umbilical artery smooth muscle cells (HUASMCs) with a recombinant fragment of fibronectin (protein III1-C) that has previously been shown to modulate fibronectin matrix assembly. III1-C inhibited HUASMC proliferation by 75% to 90%. The inhibition of growth was time dependent; III1-C had no effect on DNA synthesis after 0 to 5 hours of treatment but did have an effect at 24 hours and beyond. III1-C did not stimulate apoptosis in these cells, indicating that the inhibition of proliferation was not due to an induction of programmed cell death. The effects of III1-C on cell growth were only specific for normal diploid smooth muscle cells. III1-C had no effect on the proliferation of IMR-90 fibroblasts, endothelial cells, NIH 3T3 cells, or the rat aortic smooth muscle cell line A7r5. However, III1-C did inhibit proliferation by primary rat aortic smooth muscle cells. An analysis of HUASMC fibronectin receptor (integrin alpha5beta1) distribution revealed that III1-C did not inhibit alpha5beta1 localization to focal contacts. Moreover, III1-C had no effect on the relative expression levels of seven different integrin subunits on HUASMCs. However, III1-C did inhibit fibronectin matrix assembly by rat aortic smooth muscle cells, HUASMCs, A7r5 cells, IMR-90 cells, and endothelial cells. An analysis of fibronectin synthesis indicated that the inhibition of fibronectin matrix assembly by III1-C was not due solely to a decrease in fibronectin synthesis. Finally, treatment of HUASMCs with anti-fibronectin monoclonal antibody L8 (which is known to inhibit fibronectin matrix assembly) also decreased the rate of HUASMC DNA synthesis. These results demonstrate that III1-C inhibits VSMC proliferation and suggest that this effect may be mediated by the inhibition of fibronectin matrix assembly.
Mercurius
K O
KO
Department of Pathology, University of Chicago, Ill 60637, USA.
Morla
A O
AO
D000818:Animals; D001672:Biocompatible Materials; D016466:CHO Cells / Q000737:chemistry / Q000166:cytology; D002455:Cell Division / Q000187:drug effects; D003094:Collagen; D006224:Cricetinae; D004247:DNA / Q000096:biosynthesis; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000737:chemistry / Q000502:physiology*; D005353:Fibronectins / Q000494:pharmacology*; D006801:Humans; D007797:Laminin / Q000032:analysis; D009131:Muscle, Smooth, Vascular / Q000737:chemistry / Q000166:cytology* / Q000187:drug effects; D010446:Peptide Fragments / Q000494:pharmacology; D011509:Proteoglycans; D017469:Receptors, Fibronectin / Q000032:analysis; D014469:Umbilical Arteries / Q000166:cytology; D014471:Umbilical Veins / Q000166:cytology
D001672:Biocompatible Materials; D004338:Drug Combinations; D005353:Fibronectins; D007797:Laminin; D010446:Peptide Fragments; D011509:Proteoglycans; D017469:Receptors, Fibronectin; C059485:matrigel; D003094:Collagen; D004247:DNA